Thu, 27 Jul 2023 15:00:00 +0900 hourly 1 /release/202307247386 Thu, 27 Jul 2023 15:00:00 +0900 AI Medical Service AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of di... AI Medical Service Inc.
AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement with Stanford University School of Medicine (hereinafter Stanford Medicine), one of the world’s top medical research institutes, and will begin research activities in August 2023. AIM is the first Japanese company to sign a joint research agreement with Stanford Medicine in the field of endoscopic AI.
 
Content and Objective of Joint Research
AIM is now working toward receiving regulatory approval in Japan for its endoscopic AI product designed to identify early-stage gastric cancer. Its collaboration with Stanford Medicine will facilitate joint research designed to verify the applicability of Japanese endoscopic AI in the United States.
 
Gastric cancer is the fourth most common cause of cancer death worldwide, and approximately 26,000 cases of gastric cancer are newly diagnosed in the United States each year.
 
Stanford Medicine is located in the center of America’s West Coast, a diverse region where 58% of the population belongs to various minority groups. Gastric cancer is noteworthy for its high prevalence among Asian communities. Stanford Medicine established CARE (Stanford Center for Asian Health Research and Education) in 2018 with the mission to improve health outcomes among members of the Asian community through increased knowledge and education.
 
Comment from Dr. Joo Ha Hwang, Professor of Medicine (Gastroenterology & Hepatology) and, by courtesy, of Surgery
 
Photo1: https://cdn.kyodonewsprwire.jp/prwfile/release/M107153/202307247386/_prw_PI1fl_d5AIhRHb.jpg
 
"We are excited to collaborate with AI Medical Service Inc. in evaluating their AI platform for detecting early gastric cancer. This is an important issue in the United States because the incidence of early gastric cancer is relatively high in several immigrant populations, especially East Asians; however, the detection of early gastric cancer remains low because lesions are often subtle and difficult to identify. We look forward to evaluating this technology in clinical studies at Stanford Medicine where we have a diverse population of ethnicities who are considered to be at higher risk for gastric cancer."
 
About AI Medical Service Inc.
AI Medical Service (AIM) is a Tokyo-based med-tech company established with the mission to "Save Lives All Over the World." Japan leads the world in endoscopic diagnosis and treatment, providing firms and researchers with access to large amounts of high-quality data. AIM is the leading player in the field of endoscopic AI, engaging in joint research with more than 100 medical institutions. By bringing endoscopic AI to the real-world clinical setting as soon as possible, AIM aims to reduce the number of missed cancer diagnoses and save lives around the world.
 
For more company information, please visit: /attach/202307247386-O2-9IDB3I69.pdf
 
About CEO of AI Medical Service Inc., Dr. Tomohiro TADA, M.D., Ph.D.
 
Photo2: https://cdn.kyodonewsprwire.jp/prwfile/release/M107153/202307247386/_prw_PI2fl_Dg6FLFei.jpg
 
Dr. Tomohiro TADA is the CEO of AI Medical Service Inc., the chairperson of Tada Tomohiro The Institute of Gastroenterology & Proctology as well as Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, the University of Tokyo Hospital. Dr. TADA received his M.D. in 1996 and Ph.D. in 2005 from the University of Tokyo. He trained in colorectal surgery at the University of Tokyo Hospital.
 
For related press release, please visit: /attach/202307247386-O1-6CC385B4.pdf
]]> /release/202204200183 Tue, 26 Apr 2022 16:00:00 +0900 AI Medical Service AI Medical Service Inc. Announces 8 Billion JPY (US$70 M) Series C Financing Led by SoftBank Vision... AI Medical Service Inc.
AI Medical Service Inc. Announces 8 Billion JPY (US$70 M) Series C Financing Led by SoftBank Vision Fund 2 (SVF2)
 
AI Medical Service Inc. (hereinafter AIM), the Tokyo-based med-tech company using deep learning technology to develop endoscopic AI, has announced 8 billion JPY (US$70 million) of financing led by SoftBank Vision Fund 2 (SVF2) and joined by existing investors Globis Capital Partners, World Innovation Lab (WiL), and Incubate Fund. SoftBank Vision Fund is one of the largest technology investment funds in the world. It has invested $129 billion in the AI industry from the time of its inception until the end of 2021 (*). AIM will use the proceeds of the Series C financing round to accelerate the global adoption of endoscopic AI and finance the development of an in-house cloud-based platform.
 
Logo: /prwfile/release/M107153/202204200183/_prw_PI2fl_5z13pfEM.jpg
 
Mission of AIM
Worldwide, approximately 30% of cancer mortality can be attributed to gastrointestinal (GI) cancer, the largest of any cancer grouping in the world as well as in Japan. Many cases of GI cancer can be treated successfully if they are detected at an early stage, but the prospects for recovery diminish substantially in the case of late-stage detection. Currently, only an endoscopic exam can detect GI cancer at its early stages. By increasing the accuracy of endoscopic diagnostics with AI, AIM is working to promote the early detection of cancer and save lives all over the world.
 
Image1: /prwfile/release/M107153/202204200183/_prw_PI1fl_6U7u290q.jpg
 
Positioning of Japanese Endoscopic Medicine
Japan is the origin of endoscopic medicine and leads the world in its development and practice. Due to this storied history, endoscopic data collected in Japan is the world’s best in terms of both quality and quantity. Consequently, endoscopic AI developed utilizing Japanese expertise has great potential to be victorious in the global market.
 
Image2: /prwfile/release/M107153/202204200183/_prw_PI4fl_Mwb8c1Aw.jpg
 
Collaboration with SoftBank Group Through its collaboration with the SoftBank Group, AIM will promote the worldwide adoption of endoscopic AI, first created in Japan using the knowledge and experience of expert endoscopists. This endoscopic AI will first be distributed on-premises, but distribution will eventually transition to a cloud platform to be developed by AIM. Realizing the vision of cloud-based endoscopic AI will allow people around the world to access the latest endoscopic medicine, contributing to vastly reduced cancer mortality.
 
Image3: Global Expansion of Endoscopic AI
/prwfile/release/M107153/202204200183/_prw_PI3fl_YubQoD9k.jpg
 
AIM Direction from Series C Financing Round
1. Acceleration of global business development
- Driving joint research and product development with medical institutions in the U.S., Asia-Pacific region, etc.
- Acquiring the talent necessary to expand global business
 
2. Developing a proprietary cloud platform to eliminate GI cancer around the world
- Creating an in-house cloud platform that connects endoscopy rooms around the world to AIM’s endoscopic AI.
 
Comments from Investors, Partners and CEO at AI Medical Service: /prwfile/release/M107153/202204200183/_prw_PA1fl_aZ3XysvT.pdf
 
Note:
(*) Total investment by SVF1 and SVF2 since inception to end of 2021, cited from the presentation material for SoftBank Group Corp.’s Earnings Investor Briefing for Q3 FY2021.
 
About AI Medical Service Inc.
AI Medical Service (AIM) is a Tokyo-based med-tech company established with the mission to “Save Lives All Over the World.” Japan leads the world in endoscopic diagnosis and treatment, providing firms and researchers with access to large amounts of high-quality data. AIM is the leading player in the field of endoscopic AI, engaging in joint research with more than 100 medical institutions. By bringing endoscopic AI to real-world clinical setting as soon as possible, AIM aims to reduce the number of missed cancer diagnoses and save lives around the world.
 
Company: AI Medical Service Inc.
Address: Hareza Tower 11F, 1-18-1 Higashiikebukuro, Toshima-ku, Tokyo 170-0013, Japan
CEO: Tomohiro Tada
Founded: September 1, 2017
Business: Development of endoscopic AI
URL: https://www.ai-ms.com/en
]]>